University of Surrey

Test tubes in the lab Research in the ATI Dance Research

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.

Blonde, L and Russell-Jones, D (2009) The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab, 11 Sup. pp. 26-34.

Full text not available from this repository.

Abstract

Liraglutide is a new glucagon-like peptide-1 (GLP-1) receptor agonist and a true GLP-1 analogue. After successful phase 2 studies, liraglutide was assessed in a series of phase 3 trials [(Liraglutide Effect and Action in Diabetes (LEAD)] designed to demonstrate efficacy and safety across the continuum of type 2 diabetes antihyperglycaemic care, both as monotherapy and in combination with commonly used oral antidiabetic drugs (OADs). The LEAD programme also compared liraglutide with other OADs. As a monotherapy, liraglutide demonstrated significant improvements in glycaemic control in comparison with glimepiride. When combined with one or two OADs, reductions in haemoglobin A1c, fasting plasma glucose and postprandial glucose were generally greater with liraglutide than with comparators. Throughout the trials, liraglutide was associated with weight reduction; in most instances, the reduction from baseline was significantly greater than that seen with comparators. Improvements in assessments of beta-cell function were consistently shown with liraglutide treatment across all trials. Furthermore, reductions in systolic blood pressure were reported. Liraglutide was associated with a low risk of hypoglycaemia and was generally well tolerated. The majority of adverse effects were gastrointestinal, the most frequent of which was nausea.

Item Type: Article
Authors :
NameEmailORCID
Blonde, LUNSPECIFIEDUNSPECIFIED
Russell-Jones, Ddavidrussell-jones@nhs.netUNSPECIFIED
Date : December 2009
Identification Number : https://doi.org/10.1111/j.1463-1326.2009.01075.x
Uncontrolled Keywords : Blood Glucose, Blood Pressure, Clinical Trials, Phase II as Topic, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Risk Factors, Treatment Outcome
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 09:05
Last Modified : 17 May 2017 09:05
URI: http://epubs.surrey.ac.uk/id/eprint/822176

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800